Table 1 Patient and tumour characteristics of TNBC
Baseline characteristics (n = 83) | N (% or range) |
|---|---|
Age (mean) | 52 (29–78) |
AJCC stage | |
 Stage I, stage IA | 18 (21.7) |
 Stage IIA, stage IIB | 52 (62.7) |
 Stage IIIA, stage IIIB, stage IIIC | 12 (14.5) |
PAM50 subtype | |
 Basal | 64 (80.7) |
 Her2 | 5 (6.0) |
 LumB | 1 (1.2) |
HRD status | |
 HR deficiency | 48 (57.8) |
 HR proficiency | 35 (42.2) |
BRCA1/2 mutation | |
 BRCA1 | 6 (7.2) |
 BRCA2 | 5 (6.0) |
BRCA1 promoter methylation | 7 (7.2) |
ACT chemotherapy response | |
 Complete response | 21 (25.3) |
 Partial response | 2 (2.4) |
 Progressive disease | 1 (1.2) |
 – | 59 (71.1) |
ACT response status | |
 Sensitive | 39 (47.0) |
 Resistant | 44 (53.0) |